There are currently 112 active clinical trials seeking participants for Dementia research studies. The states with the highest number of trials for Dementia participants are Florida, California, New York and Ontario.
Connect-Home: Alzheimer's Disease and Related Dementias
NCT06840587
Recruiting
This study is a parallel arm, cluster randomized trial (CRT) to test the efficacy of Connect-Home ADRD, a transitional care intervention focusing on Skilled Nursing Facility (SNF) patients with Alzheimer's disease and dementias and their caregivers during transitions from SNFs to home, assisted, living, and long-term care. The primary hypothesis is that the intervention will reduce caregiver strain (Aim 1) and patient neuropsychiatric symptoms (Aim 2).
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/12/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Alzheimer Disease, Dementia
Register for Updates
Genetic Characterization of Movement Disorders and Dementias
NCT02014246
Recruiting
Background: There are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a history of movement disorders or dementia. They hope to find a genetic cause of these disorders. This ca... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/10/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Dementia, Movement Disorder
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/08/2025
Locations: Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona +52 locations
Conditions: Alzheimer Disease, Dementia
Register for Updates
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
NCT06613971
Recruiting
This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: 3T Radiology, Coconut Creek, Florida
Conditions: Dementia, Dementia Alzheimer Type
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: MD Stem Cells, Westport, Connecticut +3 locations
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk
NCT06965686
Recruiting
By age 45, women's lifetime risk of dementia is estimated to be 1 in 5. Two-thirds of people currently living with a dementia diagnosis are women, and-women make up the majority of carers for people with dementia. Because women bear a larger burden of the dementia epidemic, they tend to be more fearful about dementia compared to men. Women may be especially fearful during the menopause transition, which can impact cognition. These fears can cause significant psychological distress, functional im... Read More
Gender:
FEMALE
Ages:
Between 40 years and 58 years
Trial Updated:
05/01/2025
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Menopausal, Dementia
Register for Updates
Early-Stage Partner in Care Living Alone Plus
NCT06962111
Recruiting
EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/29/2025
Locations: Arizona State University, Phoenix, Arizona
Conditions: Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Register for Updates
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/24/2025
Locations: The Neuron Clinic, Chula Vista, California +12 locations
Conditions: Agitation, Dementia
Register for Updates
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
NCT06919926
Recruiting
This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/23/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Hippocampal Overactivity, Dementia
Register for Updates
Coaching Dementia Caregivers to Master Care-Resistant Behavior
NCT05098652
Recruiting
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries follo... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
04/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Care-resistant Behavior, Dementia
Register for Updates
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
NCT05374278
Recruiting
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
04/16/2025
Locations: China Basin, UCSF, San Francisco, California
Conditions: Alzheimer Disease, Frontotemporal Dementia, Dementia
Register for Updates
Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers
NCT06940687
Recruiting
This study aims to investigate the neurophysiological effects of live music on individuals with early Alzheimer's Disease (AD), dementia, and/or mild cognitive impairment (MCI) and their caregivers. Heart rate (HR), heart rate variability (HRV), and brain activity will be measured as participant-caregiver dyads listen to preferred and improvised music performed by professional musicians. Investigators will leverage various measurement techniques including, but not limited to, electroencephalogra... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/15/2025
Locations: Firehouse 12 Studios, New Haven, Connecticut +1 locations
Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Register for Updates